Literature DB >> 7674230

Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis.

L M Buckley1, E S Leib, K S Cartularo, P M Vacek, S M Cooper.   

Abstract

OBJECTIVE: To assess the effect of low doses of corticosteriods on the bone mineral density (BMD) of patients with rheumatoid arthritis (RA).
METHODS: A cross sectional study of BMD as measured by dual photon x-ray of the femoral neck and lumbar spine (lateral view) in 139 patients with RA followed in a university setting.
RESULTS: The mean daily dose of prednisone taken by the study group was 4.15 mg/day. Patients receiving daily doses of prednisone between 1 to 4 mg/day had similar BMD to patients who were not receiving corticosteroids, but patients taking 5-9 mg/day and those taking > 10 mg/day had significantly lower BMD of the lumbar spine (84.28 and 80.51% of controls, respectively) than patients who received 1-4 mg/day (99.16% of controls). The effect of corticosteroids remained significant when other risk factors such as disease severity, disease duration, functional class, and activity level were controlled for. No significant relationship between prednisone dose and BMD of the femoral neck was seen at the low doses studied.
CONCLUSION: Low dose corticosteroid use has a significant effect on BMD of the lumbar spine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7674230

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

1.  Management of bone disease in patients on long term glucocorticoid therapy.

Authors:  J E Compston
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

2.  Body composition and vertebral fracture risk in female patients treated with glucocorticoid.

Authors:  H Kaji; T Tobimatsu; J Naito; M-F Iu; M Yamauchi; T Sugimoto; K Chihara
Journal:  Osteoporos Int       Date:  2005-12-31       Impact factor: 4.507

3.  Effects of long-term corticosteroid usage on functional disability in patients with early rheumatoid arthritis, regardless of controlled disease activity.

Authors:  Eiichi Tanaka; Ajitha Mannalithara; Eisuke Inoue; Noriko Iikuni; Atsuo Taniguchi; Shigeki Momohara; Gurkirpal Singh; Hisashi Yamanaka
Journal:  Rheumatol Int       Date:  2010-12-16       Impact factor: 2.631

4.  The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.

Authors:  Funda Tascioglu; Omer Colak; Onur Armagan; Ozkan Alatas; Cengiz Oner
Journal:  Rheumatol Int       Date:  2005-02-02       Impact factor: 2.631

5.  Comparison of ultrasound and X-ray absorptiometry bone measurements in a case control study of female rheumatoid arthritis patients and randomly selected subjects in the population.

Authors:  G Haugeberg; R E Ørstavik; T Uhlig; J A Falch; J I Halse; T K Kvien
Journal:  Osteoporos Int       Date:  2003-04-16       Impact factor: 4.507

6.  Sustained maintenance of exercise induced muscle strength gains and normal bone mineral density in patients with early rheumatoid arthritis: a 5 year follow up.

Authors:  A Häkkinen; T Sokka; H Kautiainen; A Kotaniemi; P Hannonen
Journal:  Ann Rheum Dis       Date:  2004-08       Impact factor: 19.103

7.  The effect of low-dose methotrexate on bone mineral density in patients with early rheumatoid arthritis.

Authors:  Funda Tascioglu; Cengiz Oner; Onur Armagan
Journal:  Rheumatol Int       Date:  2003-03-21       Impact factor: 2.631

Review 8.  Methotrexate intolerance in elderly patients with rheumatoid arthritis: what are the alternatives?

Authors:  Alexandros Drosos
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

9.  Oral glucocorticoid use is associated with an increased risk of fracture.

Authors:  Michael Steinbuch; Thomas E Youket; Stanley Cohen
Journal:  Osteoporos Int       Date:  2004-02-05       Impact factor: 4.507

10.  Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis.

Authors:  Kageyama Yasunori; Takahashi Masaaki; Nagafusa Tetsuyuki; Kobayashi Hayato; Nagano Akira
Journal:  Clin Rheumatol       Date:  2008-03-13       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.